Mannkind (MNKD) Capital Expenditures (2010 - 2026)
Mannkind (MNKD) reported Capital Expenditures of $267000.0 for Q1 2026, down 19.09% year-over-year from $330000.0 in Q1 2025, and up 229.61% quarter-over-quarter from -$206000.0 in Q4 2025.
Mannkind (MNKD) Capital Expenditures (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has 15 years of Capital Expenditures data on file, last reported at $267000.0 in Q1 2026.
- Capital Expenditures for Q1 2026 came in at $267000.0, down 19.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $556000.0 (down 93.35% YoY), and the FY2025 annual result was $619000.0, down 93.61% from the prior year.
- Capital Expenditures advanced to $267000.0 in Q1 2026 per MNKD's latest filing, from -$206000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $22.7 million in Q2 2023 and troughed at -$22.7 million in Q3 2023.
- A 5-year average of $1.2 million and a median of $330000.0 in 2025 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2023 and 2024: Capital Expenditures slumped 2775.79% in 2023, then soared 1127.16% in 2024.
- A 5-year view of Capital Expenditures shows it stood at $6.2 million in 2022, then sank by 112.98% to -$799000.0 in 2023, then soared by 1127.16% to $8.2 million in 2024, then plunged by 102.51% to -$206000.0 in 2025, then jumped by 229.61% to $267000.0 in 2026.
- Business Quant data shows MNKD's Capital Expenditures at $267000.0 in Q1 2026, -$206000.0 in Q4 2025, and -$622000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Mannkind | 1.21 Bn | 1.08 Bn | 82.66 Mn | 267,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 267,000.00 |
| Mar 31, 2026 | 267,000.00 |
| Dec 31, 2025 | -206,000.00 |
| Dec 31, 2025 | -206,000.00 |
| Sep 30, 2025 | -622,000.00 |
| Sep 30, 2025 | -622,000.00 |
| Jun 30, 2025 | 1.12 Mn |
| Jun 30, 2025 | 1.12 Mn |
| Mar 31, 2025 | 330,000.00 |
| Mar 31, 2025 | 330,000.00 |
| Dec 31, 2024 | 8.21 Mn |
| Dec 31, 2024 | 8.21 Mn |
| Sep 30, 2024 | -3.89 Mn |
| Sep 30, 2024 | -3.89 Mn |
| Jun 30, 2024 | 3.71 Mn |
| Jun 30, 2024 | 3.71 Mn |
| Mar 31, 2024 | 1.67 Mn |
| Mar 31, 2024 | 1.67 Mn |
| Dec 31, 2023 | -799,000.00 |
| Dec 31, 2023 | -799,000.00 |